文献速递结核与非结核分枝杆菌

马拉维肺结核患者一线抗结核药物的肺内药代动力学

Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2021-01-01

尽管按体重给药,一线药物血浆峰浓度低于治疗药物监测目标,利福平在三室均低;异烟肼和吡嗪酰胺在ELF分别比血浆高14.6倍和49.8倍,乙胺丁醇在肺泡细胞浓度最高(肺泡细胞/血浆比15.0)。血浆或肺内药代动力学未预测临床治疗反应。

要点

  • 标准剂量下一线抗结核药血浆峰浓度低于治疗药物监测目标。
  • 异烟肼、吡嗪酰胺在ELF蓄积,乙胺丁醇在肺泡细胞浓度最高。
  • 利福平在血浆、ELF和肺泡细胞中浓度均低,支持高剂量利福平试验。

核心结论

  • 一线抗结核药在血浆与肺内浓度存在差异,肺内蓄积可能解释标准方案的成功;利福平各室浓度均低,支持高剂量利福平临床试验。

主要发现

  • 尽管按体重标准给药,一线药物血浆峰浓度低于治疗药物监测目标。
  • 利福平在血浆、ELF和肺泡细胞三室浓度均低。
  • 异烟肼和吡嗪酰胺在ELF浓度分别比血浆高14.6倍(95%CI 11.2-18.0)和49.8倍(95%CI 34.2-65.3)。
  • 乙胺丁醇在肺泡细胞浓度最高,肺泡细胞/血浆比为15.0(95%CI 11.4-18.6)。
  • 血浆或肺内药代动力学未预测临床治疗反应。

临床怎么用

  • 标准剂量下应关注一线抗结核药血浆暴露不足,尤其利福平。
  • 肺内药物蓄积可能部分解释标准方案疗效,但不应据此忽视血浆低暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Further work is required to understand the intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs. This study aimed to describe the plasma and intrapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide, and ethambutol, and explore relationships with clinical treatment outcomes in patients with pulmonary tuberculosis. METHODS: Malawian adults with a first presentation of microbiologically confirmed pulmonary tuberculosis received standard 6-month first-line therapy. Plasma and intrapulmonary samples were collected 8 and 16 weeks into treatment and drug concentrations measured in plasma, lung/airway epithelial lining fluid (ELF), and alveolar cells. Population pharmacokinetic modeling generated estimates of drug exposure (Cmax and AUC) from individual-level post hoc Bayesian estimates of plasma and intrapulmonary pharmacokinetics. RESULTS: One-hundred fifty-seven patients (58% HIV coinfected) participated. Despite standard weight-based dosing, peak plasma concentrations of first-line drugs were below therapeutic drug-monitoring targets. Rifampicin concentrations were low in all 3 compartments. Isoniazid, pyrazinamide, and ethambutol achieved higher concentrations in ELF and alveolar cells than plasma. Isoniazid and pyrazinamide concentrations were 14.6-fold (95% CI, 11.2-18.0-fold) and 49.8-fold (95% CI, 34.2-65.3-fold) higher in ELF than plasma, respectively. Ethambutol concentrations were highest in alveolar cells (alveolar cell-plasma ratio, 15.0; 95% CI, 11.4-18.6). Plasma or intrapulmonary pharmacokinetics did not predict clinical treatment response. CONCLUSIONS: We report differential drug concentrations between plasma and the lung. While plasma concentrations were below therapeutic monitoring targets, accumulation of drugs at the site of disease may explain the success of the first-line regimen. The low rifampicin concentrations observed in all compartments lend strong support for ongoing clinical trials of high-dose rifampicin regimens.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. McCallum AD, Pertinez HE, Else LJ, et al. Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. Clin Infect Dis. 2021. PMID: 32856694. doi:10.1093/cid/ciaa1265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。